Literature DB >> 27660570

A Metaanalysis of Interventions to Improve Adherence to Lipid-Lowering Medication.

Richard E Deichmann1, Michael D Morledge2, Robin Ulep2, Johnathon P Shaffer2, Philippa Davies3, Mieke L van Driel4.   

Abstract

BACKGROUND: Inadequate patient adherence to a medication regimen is a major factor in the lack of success in treating hyperlipidemia. Improved adherence rates may result in significantly improved cardiovascular outcomes in populations treated with lipid-lowering therapy. The purpose of this metaanalysis was to evaluate the effectiveness of interventions aimed at improving adherence to lipid-lowering drugs, focusing on measures of adherence and clinical outcomes.
METHODS: We searched the Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, PsycINFO, and the Cumulative Index to Nursing and Allied Health Literature databases through January 14, 2015, and also used the results from previous Cochrane reviews of this title. Randomized controlled trials of adherence-enhancing interventions for lipid-lowering medication in adults in an ambulatory setting with measurable outcomes were evaluated with criteria outlined by the Cochrane Handbook for Systematic Reviews of Interventions.
RESULTS: Twenty-seven studies randomly assigning 899,068 participants to a variety of interventions were analyzed. One group of interventions categorized as intensified patient care showed significant improvement in adherence rates when compared to usual care (odds ratio 1.93; 95% confidence interval [CI] 1.29-2.88). Additionally, after <6 months of follow-up, total cholesterol decreased by a mean of 17.15 mg/dL (95% CI 1.17-33.14), while after >6 months total cholesterol decreased by a mean of 17.57 mg/dL (95% CI 14.95-20.19).
CONCLUSION: Healthcare systems that can implement team-based intensified patient care interventions, such as electronic reminders, pharmacist-led interventions, and healthcare professional education of patients, may be successful in improving adherence rates to lipid-lowering medicines.

Entities:  

Keywords:  Cholesterol; hyperlipidemias; lipid-regulating agents; medication adherence

Year:  2016        PMID: 27660570      PMCID: PMC5024803     

Source DB:  PubMed          Journal:  Ochsner J        ISSN: 1524-5012


  45 in total

1.  Poor adherence with hypolipidemic drugs: a lost opportunity.

Authors:  R T Tsuyuki; T J Bungard
Journal:  Pharmacotherapy       Date:  2001-05       Impact factor: 4.705

2.  The effects of postal and telephone reminders on compliance with pravastatin therapy in a national registry: results of the first myocardial infarction risk reduction program.

Authors:  R M Guthrie
Journal:  Clin Ther       Date:  2001-06       Impact factor: 3.393

3.  Increasing the detection and response to adherence problems with cardiovascular medication in primary care through computerized drug management systems: a randomized controlled trial.

Authors:  Robyn Tamblyn; Kristen Reidel; Allen Huang; Laurel Taylor; Nancy Winslade; Gillian Bartlett; Roland Grad; André Jacques; Martin Dawes; Pierre Larochelle; Alain Pinsonneault
Journal:  Med Decis Making       Date:  2009-08-12       Impact factor: 2.583

4.  Influence of the use of functional foods enriched with phytosterols/-stanols on adherence to statin therapy.

Authors:  Simone R B M Eussen; Marcel L Bouvy; Cathy J M Rompelberg; Menno E van der Elst; Johan Garssen; Marco H Oosterveld; Anthonius de Boer; Johan J de Gier; Henk J van Kranen; Olaf H Klungel
Journal:  Pharmacoepidemiol Drug Saf       Date:  2011-06-07       Impact factor: 2.890

Review 5.  Identifying relevant studies for systematic reviews.

Authors:  K Dickersin; R Scherer; C Lefebvre
Journal:  BMJ       Date:  1994-11-12

6.  Efficacy and compliance with cholestyramine bar versus powder in the treatment of hyperlipidemia.

Authors:  M E Sweeney; B J Fletcher; C R Rice; K A Berra; C M Rudd; G F Fletcher; R S Superko
Journal:  Am J Med       Date:  1991-04       Impact factor: 4.965

7.  Full coverage for preventive medications after myocardial infarction.

Authors:  Niteesh K Choudhry; Jerry Avorn; Robert J Glynn; Elliott M Antman; Sebastian Schneeweiss; Michele Toscano; Lonny Reisman; Joaquim Fernandes; Claire Spettell; Joy L Lee; Raisa Levin; Troyen Brennan; William H Shrank
Journal:  N Engl J Med       Date:  2011-11-14       Impact factor: 91.245

8.  Full prescription coverage versus usual prescription coverage after coronary artery bypass graft surgery: analysis from the post-myocardial infarction free Rx event and economic evaluation (FREEE) randomized trial.

Authors:  Alexander Kulik; Nihar R Desai; William H Shrank; Elliott M Antman; Robert J Glynn; Raisa Levin; Lonny Reisman; Troyen Brennan; Niteesh K Choudhry
Journal:  Circulation       Date:  2013-09-10       Impact factor: 29.690

9.  Adherence to statin treatment and readmission of patients after myocardial infarction: a six year follow up study.

Authors:  L Wei; J Wang; P Thompson; S Wong; A D Struthers; T M MacDonald
Journal:  Heart       Date:  2002-09       Impact factor: 5.994

10.  Multifaceted intervention to improve medication adherence and secondary prevention measures after acute coronary syndrome hospital discharge: a randomized clinical trial.

Authors:  P Michael Ho; Anne Lambert-Kerzner; Evan P Carey; Ibrahim E Fahdi; Chris L Bryson; S Dee Melnyk; Hayden B Bosworth; Tiffany Radcliff; Ryan Davis; Howard Mun; Jennifer Weaver; Casey Barnett; Anna Barón; Eric J Del Giacco
Journal:  JAMA Intern Med       Date:  2014-02-01       Impact factor: 21.873

View more
  2 in total

1.  Clinical Use of the Edmonton Obesity Staging System for the Assessment of Weight Management Outcomes in People with Class 3 Obesity.

Authors:  Raymond Kodsi; Ritesh Chimoriya; David Medveczky; Kathy Grudzinskas; Evan Atlantis; Abd A Tahrani; Nic Kormas; Milan K Piya
Journal:  Nutrients       Date:  2022-02-24       Impact factor: 5.717

2.  Blood lipid levels and treatment following an acute coronary syndrome or coronary intervention - Journey from hospital to cardiac rehabilitation.

Authors:  David Rott; Ilan Hay; Irene Nabutovsky; Alexis Heller; Daniel Breitner; Robert Klempfner
Journal:  Int J Cardiol Cardiovasc Risk Prev       Date:  2022-08-17
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.